Abstract

E Derom, outside of the submitted work, reports financial support from Boehringer Ingelheim, Actelion, AstraZeneca and Cipla for consultancy work, financial support from Chiesi, AstraZeneca and CSL Behring for advisory board attendance, and research support from Boehringer Ingelheim and GlaxoSmithKline.

M Fležar has received personal fees from Boehringer Ingelheim and institutional financial support from Novartis.

L Grönke and F Voß are employees of Boehringer Ingelheim Pharma GmbH & Co. KG.

R Buhl reports financial support to his institution from Boehringer Ingelheim during the conduct of the study and, outside of the submitted work, financial support from Boehringer Ingelheim, AstraZeneca, Chiesi, Novartis, Teva, Roche and GlaxoSmithKline for attendance at advisory boards and speaking activities, and research support to his institution from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Roche.